Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
Authors:
Open Access
- 19 January 2010
- journal article
- Published by Wiley in BJU International
- Vol. 106 (8) , 1216-1222
Abstract
OBJECTIVE: To test whether the expression of human epidermal growth factor receptor 2 (HER‐2) is of prognostic value in a contemporary cohort of patients with urothelial carcinoma of the urinary bladder (UCB). PATIENTS AND METHODS: Tissue microarrays of 198 patients were constructed and immunohistochemical stainings were performed on the primary tumours and on lymphatic nodal metastases. All patients were treated with radical cystectomy (RC) and regional lymphadenectomy for UCB. HER‐2 expression was assessed using continuous HER‐2 expression scores (ranging from 0.1 to 3.9) generated using an automated cellular imaging system. Scores of ≥1.0 in at least 10% of tumour cells were regarded as HER‐2 positive. We correlated HER‐2 scores with pathological and clinical variables, including disease recurrence and cancer‐specific mortality. RESULTS: Of 198 patients undergoing RC with lymphadenectomy, there was HER‐2 positivity in 55 primary tumours (27.8%) compared with 44.2% of the evaluable positive lymph nodes ( P < 0.001). HER‐2 positivity was significantly associated with the presence of lymphovascular invasion (LVI; P = 0.026). With a median (range) follow‐up of 35.4 (1.3–176.1) months, 101 patients (51.0%) had UCB recurrence and 82 patients (41.4%) died from the disease. In multivariable analyses that adjusted for the effects of pathological tumour stage, grade, LVI, lymph node metastasis and adjuvant chemotherapy, HER‐2 positive patients were at increased risk for both UCB recurrence (hazard ratio [HR] 1.955, P = 0.003) and UCB‐specific mortality (HR 2.066, P = 0.004) compared with patients with negative HER‐2 expression. CONCLUSION: A positive HER‐2 status is associated with aggressive UCB and provides independent prognostic information for UCB recurrence and mortality. Assessment of HER‐2 status can be used to identify patients at high risk of disease progression who may benefit from adjuvant HER‐2‐targeted mono‐ or combined therapy after RC.Keywords
This publication has 30 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Molecular markers in bladder cancerCurrent Opinion in Urology, 2008
- Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder CancerJournal of Urology, 2008
- Trastuzumab (Herceptin®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patientsEuropean Journal of Cancer, 2006
- Novel Approach of Human Epidermal Growth Factor Receptor 2 Detection in Noninvasive and Invasive Transitional Cell Carcinoma of the BladderJournal of Urology, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?European Journal of Cancer, 2004
- HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implicationsInternational Journal of Cancer, 2002
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994